The stock is trading at $2.92 a tad higher than $2.17, the 50 day moving average and which is a tad above the 200 day moving average of $1.70. The 50 day moving average was up $0.75 and the 200 day average moved up $1.22. BioScrip, Inc. shares had a trading volume of 1,272K in the last trading session. Volume was down 10.04% under the stocks average daily volume.
Short traders are feeling a little more bullish on the company recently if you take into consideration the change in short interest. The firm saw a fall in short interest of -1.46% as of May 31, 2017 from the last reporting period. Short shares fell from 23,372,135 to 23,030,122 over that period. The short-interest ratio decreased to 11.6 and the percentage of shorted shares is 0.19% as of May 31.
BioScrip, Inc. (NASDAQ:BIOS) has been the object of insider buying activity recently. CFO Jeffrey M. Kreger purchased 10,000 shares at an average price of $1.32 on Fri the 11th. That brings the CFO’s holdings to $29,869 as recorded in a recent Form 4 SEC filing. CEO Daniel E. Greenleaf disclosed the purchase of 16,000 shares of (BIOS). The shares were purchased at an average price of $1.30. Greenleaf now owns $20,800 of the stock per the Form 4 SEC filing.
R. Carter Pate, Director acquired $26,000 worth of shares at an average price of $1.30 on November 10th. That brings Pate’s holdings to $109,200 per an SEC filing yesterday.
Here are some other firms who have updated their holdings. Creative Planning cut its investment by selling 1,000 shares a decrease of 21.3% in the quarter. Creative Planning controls 3,700 shares with a value of $10,000. The total value of its holdings increased 25.0%. As of the end of the quarter Morgan Stanley had disposed of a total of 5,000 shares trimming its holdings by 50.0%. The value of the investment in (BIOS) decreased from $10,000 to $9,000 a change of $1,000 since the last quarter.
Tower Research Capital LLC (trc) reduced its ownership by shedding 2,833 shares a decrease of 63.7% from 12/31/2016 to 03/31/2017. Tower Research Capital LLC (trc) currently owns 1,616 shares worth $3,000. The value of the position overall is down by 40.0%. Goldman Sachs Group Inc divested its holdings by selling 24,167 shares a decrease of 62.4% as of 03/31/2017. Goldman Sachs Group Inc now controls 14,590 shares valued at $25,000. The value of the position overall is down by 37.5%.
Jefferies issued its first research report on the stock with an initial rating of “Buy”. On August 11, 2015 the stock rating was rated “Neutral” in a report from SunTrust Robinson Humphrey down from the previous “Buy” rating.
On May 11 SunTrust Robinson Humphrey made no change to the stock rating of “Buy” but lowered the price expectation to $5.00 from $7.00. May 8 investment analysts at Jefferies kept the stock rating at “Buy” and lowered the price expectation from $8.00 to $6.50.
Equity analyst Craig-Hallum initiated coverage on BIOS setting a rating of “Buy” and establishing a price target of $7.00. On March 4 Jefferies left the stock rating at “Buy” but moved down the price target to $8.00 from $9.50.
The company is trading up by 1.74 percent from yesterday’s close. As of the last earnings report the EPS was $-0.57 and is expected to be $-0.38 for the current year with 120,982,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.06 and the next full year EPS is projected to be $-0.20.
BioScrip, Inc., launched on March 22, 1996, is involved in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications..